Drug
Cs3007
Cs3007: highest development phase Phase 1/2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CS3007 (BLU-285) NCT04254939 | Phase 1/2 | Gastrointestinal Stromal Tumors |
Latest
No recent events.
Follow Cs3007 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.